Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Brian Moore who wrote (17655)	3/18/1998 9:13:00 PM
From: Andreas Helke	Read Replies (1) \| Respond to of 32384

NDA effects: the typical pattern seem to be to get up in anticipation of the NDA filing. What happens after the filing or the approval is not particular predictable. Except that denial of approval is good for an 20% to 75% down day. Agouron went all the way from $15 to to $50 in a pretty straight line in anticipation of the Viracept NDA filing. After the filing it went back down to $40. The NDA approval just caused a one day spike. Agouron recently made another trip to $30 upon some not so good news about a dissolved development partnership for cancer with Roche. Take a look at this chart techstocks.com The run up to the NDA filing started in juli 1996. Andreas